Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Chronic Inflammation and Blood Cancer

Version 1 : Received: 17 November 2022 / Approved: 21 November 2022 / Online: 21 November 2022 (03:32:01 CET)
Version 2 : Received: 24 November 2022 / Approved: 24 November 2022 / Online: 24 November 2022 (02:55:44 CET)

How to cite: Tzenios, N.; Tazanios, M.; Chahine, M. Chronic Inflammation and Blood Cancer. Preprints 2022, 2022110365. https://doi.org/10.20944/preprints202211.0365.v2 Tzenios, N.; Tazanios, M.; Chahine, M. Chronic Inflammation and Blood Cancer. Preprints 2022, 2022110365. https://doi.org/10.20944/preprints202211.0365.v2

Abstract

Chronic inflammation may have a detrimental impact on human health as it tends to result in cancer. In addition, it is often linked to different steps that participate in tumorigenesis, including cellular transformation, survival, promotion, invasion, proliferation, angiogenesis, and metastasis. Hence, inflammation predisposes cancer development and plays a vital role in promoting all tumorigenesis stages. Inflammation is caused by many factors, such as bacterial and viral infections, tobacco smoking, autoimmune diseases, obesity, asbestos exposure, and many others, increasing cancer risk. Moreover, cancer can be enhanced by mutations that proceed to cancer progression. Consequently, it leads to immunosuppression and provides a favorable background for tumor development. Although many studies address the question of relationships between inflammation and cancer development, little attention is paid to the link between inflammation and blood cancer. Therefore, the current study reviews the role of inflammation in cancer development, particularly in blood cancer. A meta-analysis research approach meets the research objective and answers the research question. The review results indicate that chronic inflammation directly relates to the development of many cancer types, blood cancer in particular.

Keywords

blood cancer; chronic inflammation; inflammation; mutation; tumor

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (1)

Comment 1
Received: 24 November 2022
Commenter: Nikolaos Tzenios
Commenter's Conflict of Interests: Author
Comment: We have updated a few citations.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.